Skip to main content

Unfortunately we don't fully support your browser. If you have the option to, please upgrade to a newer version or use Mozilla Firefox, Microsoft Edge, Google Chrome, or Safari 14 or newer. If you are unable to, and need support, please send us your feedback.

We'd appreciate your feedback.Tell us what you think!

Elsevier
Publish with us

Profile

Matt Simon

Matthew Simon

Denali Therapeutics, USA

Matt Simon is a Principal Scientist at Denali Therapeutics interested in drug delivery to the CNS and RNA based therapeutic strategies for neurodegenerative diseases. Matt received his PhD in neuroscience at Oregon Health & Science University, studying brain-CSF interactions in aging and neurodegeneration. He has been at Denali Therapeutics for 6 years, using in vivo models of neurodegeneration to investigate brain penetrant therapeutic strategies, and profile disease mechanisms and biomarkers. His current research focuses on the delivery and impact of RNA modifying therapeutics for treatment of CNS diseases.